Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1554)	3/26/2002 11:54:46 AM
From: tuck	Respond to of 1728

Nigel, I don't think AFFX is competing with PDGM at Monsanto, as the Monsanto collaboration with PDGM involves the latter's GeneFunction Factory: Message 16416537 Though obviously this is a direct challenge to the Agilent/PDGM effort, which also involves putting the Arabidopsis genome on a chip. Looks like a horse race, and I have no way of handicapping it except to say that in general, AFFX enjoys better market acceptance. I note that the PDGM/A effort was expected to be available at the end of '01, but I haven't heard anything about it being launched. Which, aside from the blow-up with CEO Ryals, might explain why PDGM is wallowing in $1s. Cheers, Tuck

To: nigel bates who wrote (1554)	6/13/2002 11:39:51 AM
From: tuck	Read Replies (2) \| Respond to of 1728

Anybody know what this means financially for AFFX? No terms mentioned here, wonder if there has been mention of them in PRs about similar deals in the past. >SANTA CLARA, Calif. and OSS, Netherlands, June 13 /PRNewswire-FirstCall/ -- Affymetrix, Inc. (Nasdaq: AFFX - News) and Organon announced today that they have entered into a multi-year EasyAccess(TM) Silver agreement under which Organon, an international pharmaceutical company, will gain broad access to Affymetrix' standard and custom GeneChip® arrays, instrumentation and software for use in its pharmaceutical research and development activities. "We are extremely pleased that Organon chose our GeneChip platform for pharmaceutical research and development and to expand their relationship with Affymetrix going forward," said Mitch Kennedy, general manager, Affymetrix European Business Unit. "Organon's decision demonstrates the growing demand for and standardization on GeneChip technology as customers in Europe continue to recognize the benefits of GeneChip technology for conducting whole-genome and directed analysis." "Organon has established a strong and productive portfolio of strategic research alliances. The current agreement with Affymetrix strengthens this portfolio and adds important tools for the discovery of differentially expressed genes. This will further improve our ability to identify and validate novel drug targets in our research programs," stated Driek Vergouwen, Managing Director R&D at Organon.<< snip Cheers, Tuck